NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Invenra

Invenra

Private
Madison, WisconsinHealthcare & Life Scienceshttps://invenra.com/

Last Round

Debt

Apr 10, 2020

Total Funding Raised

$19.84M

Company Overview

Invenra is a biotechnology company that specializes in the discovery and development of next-generation multispecific antibody therapeutics for oncology and other disease applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Usage-Based SaaS

AI Layer

Application

Keywords

multispecific antibodiesantibody discoverybiologicsdrug discovery platformB-BodySNIPERoncology therapeuticsantibody engineeringbiotech platformtherapeutic candidatesdrug developmentantibody designbiotech discoveryprotein engineeringantibody therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invenra Comps

Public and private peers based on sector, stage, and business model.

Invenra comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Invenra Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 10, 2020
Series BOct 16, 2018
Series AOct 5, 2017
Series A ExtensionJul 20, 2016
Series A ExtensionAug 13, 2015
VC Round
Jan 28, 2015

Key People

Founding team and executive leadership

Tim Daley

Chief Financial Officer

Executive Team

Invenra Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 22, 2025

    Partnering with Xcellon Biologics to develop new antibody therapeutics.

  • Jul 14, 2025

    Dr. Alan J. Korman joins the Scientific Advisory Board.

Invenra Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Invenra Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Invenra's valuation, stock price, and market status.

Firmographic Details

HeadquartersMadison, Wisconsin
Employee Range55
Year Founded2011
Last FundingApr 10, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.